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INTRODUCTION
Rheumatoid Arthritis(RA) is a chronic, autoimmune, inflammatory disorder of 
unknown aetiology1, that affects ~1% of general population2,0.5% of adult 
population worldwide3.It primarily involves smaller and larger synovial joints 
causing symmetric polyarthritis1.It may also affect many other organs and 
tissues including heart, kidneys, lungs, eyes, salivary glands, blood vessels and 
nerve tissue.
         Among all the extra-articular involvement, CardioVascular Disease 
(CVD) is the leading cause of mortality in RA patients and its accounts for 
35%-51% of all mortality in RA patients4, with a decrease in life expectancy by 
3-10 years.3 Coronary Heart Disease (CHD) risk is greater in patients with RA 
by approximately 1.5-fold to 2-fold (i.e., relative risk).5 The excess vascular 
risk manifests differently in RA patients compared with patients without RA, 
with less angina, but more sudden deaths and unrecognized myocardial 
infarctions.5
The process of atherosclerosis in RA is a dynamic inflammatory process.6 This 
inflammation leads to impaired endothelial dysfunction that causes systemic 
release of inflammatory mediators like Tumor Necrosis Factor-α (TNF-
α),Interleukin-1 (IL) and IL-6.1 Atherosclerosis begins with endothelial 
activation, leukocyte recruitment, lipid oxidation, plaque destabilization and 
thrombosis.6
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               Framingham Heart study established a clear paradigm in which higher 
Total cholesterol (TC) level is associated with increased cardiovascular risk 
inGeneralpopulation. But in RA patients a different relationship was observed 
– that is lower TC is associated with increased cardiovascular risk.7 Thus an 
absence of abnormal lipid profile does not rule out the possibility of coronary 
vascular disease in these patients.
           In RA patient lipid profile varies depending on disease activity and 
duration. In these patients, inflammation causes changes in both increased 
Lipoprotein(a) [Lp(a)] and decreased High Density Lipoprotein (HDL) leading 
to dyslipoproteinemia.1
Lp(a) is one of the important risk factors for premature atherosclerosis.1
Several studies show a direct relationship between Lipoprotein(a) and coronary 
artery disease in general population and Type-2 Diabetes Mellitus (DM).8 In 
our study we estimate the relationship between Lp(a) and Dyslipoproteinemia 
with cardiovascular risk in RA patients.
        This subclinical atherosclerosis can  demonstrated by increased Carotid 
artery Intima Media Thickness (CIMT).6CIMT is a doppler measurement of 
carotid artery, that measures the intima, media layers- where the atheroma 
begins. 
It is considered as a good marker of atherosclerosis in its initial stage. 
Both Carotid plaques and Carotid artery IMT are associated with higher risk of 
cardiovascular mortality.9
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The purpose of our present study was to measure Carotid IMT and Carotid 
plaques by using high resolution B-mode ultrasound and colour doppler to 
assess the existence of subclinical atherosclerosis in RA patients and healthy 
controls.10
Hence, we find out the correlation between Lp(a) and cIMT and lipid 
profile in RA patients and control groups.  
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REVIEW OF LITERATURE
Rheumatoid arthritis (RA):
      RA is a chronic inflammatory autoimmune disease of unknown aetiology 
characterized by a symmetric, peripheral polyarthritis13. It is the most common 
form of chronic inflammatory arthritis and often results in joint damage and 
physical disability13. It is a systemic disease and hence may affect other organs 
including heart, lungs, eyes and skin.14
     Compared to men, RA disease develops 2 to 3 times more common in 
women.14 The incidence of RA increases between 25 and 55years of age, after 
which it plateaus until the age of 75 and then decreases13. For men symptoms 
develop later in life.14
Aetiology:
The exact aetiology of RA is unknown.16 The probable risk factors include. 
(I) There may be a Genetic basis for development of RA disease13
               (i)The alleles known to confer the greatest risk of RA are located 
within the Major HistoCompatibility Complex (MHC)5. It has been estimated 
that one-third of the genetic risk for RA resides within MHC locus. Most but 
not all of this risk is associated with allelic variation in the HLA-DRB1gene 
(which encodes the MHC IIβ-chain molecule). The disease-associated HLA-
DRB1alleles share an amino acid sequence at positions 70-74in the third 
hypervariable regions of the HLA-DR β-chain known as Shared Epitope (SE). 
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Carriership of the SE alleles is associated with production of Anti-Cyclic 
Citrullinated Peptides Antibody (Anti-CCP)  and worse disease outcomes13.
(ii) Genome-Wide Association Studies (GWAS) are based on the detection of 
Single-Nucleotide Polymorphisms (SNPs).
             (iii)Among the best examples of the non-MHC genes contributing to 
the  risk of RA is gene encoding Protein Tyrosine Phosphatase Non-receptor 22 
(PTPN22)13
(2)Estrogen plays an important role.13,16
(i) Enhances immune response. 
(ii)Estrogen can stimulate production of TNF-α, a major cytokine in the 
pathogenesis of RA.
(3) Environmental factors:
(1) Infectious aetiology:5,13
                (i) bacterial -Proteus, Enteric bacteria.
                (ii)viral infections -Epstein-Barr virus (EBV), Parvovirus-B19
(2)Cigarette smoking increases the risk of the disease in men.
Smoking increasethe risk of RA with HLA-DR4 and act   synergistically 
with HLA-DRB1.16Long term exposure to tobacco smoke has capacity 
toinduce citrullination of cellular proteins in the lung and stimulate the 
expression of a neoepitope. Neoepitope is capable of inducing self-reactivity 
and leads to formation of immune complexes and joint inflammation.13
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(3) Exposure to silicone dust, asbestos, wood and mineral oil has also been 
linked toan increased for anti-CCP antibody-positive RA.13
Pathogenesis of RA:13
Genetic predisposition along with environmental factors may trigger the 
development of RA, with subsequent synovial Tcell activation. CD4+ T cells 
become activated by Antigen-Presenting Cells (APCs) through interactions 
between the Tcell receptor and Class II MHC-peptide antigen (signal 1).
         Inside the joint ligands binding Toll-like Receptors (TLRs) may further 
stimulate activation of APCs. Synovial CD4+Tcells differentiate into TH1and 
TH17 cells; each with their distinctive cytokine profile.CD4+TH cells in turn 
activate B cells. Immune complexes (like Rheumatoid factors (RFs), anti-CCP 
antibodies) may form inside the joint and activating the complement pathway 
and amplifying inflammation.           
T effector cells stimulate synovial macrophages(M) and fibroblast (FB) to 
secrete proinflammatory mediators -TNF-α. TNF-α upregulates adhesion 
molecules on endothelial cells and promoting leukocyte influx into the joint. It 
also stimulates the production of other inflammatory mediators, like IL-1,IL-6 
and Granulocyte-Macrophage Colony-Stimulating Factor(GM-CSF). TNF-α 
has a critically important function in regulating the balance between bone 
destruction and formation.
20
Fig 1: Show pathophysiological mechanisms of RA13.
TNF-α stimulates osteoclastogenesis. However, it is not sufficient byitself to 
induce the differentiation of osteoclast precursors (Pre-OC) into activated 
osteoclasts capable of eroding bone. Osteoclast differentiation requires the 
presence of colony stimulating factor and Receptor Activator of Nuclear 
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Factor-Kb(RANK) ligand(RANKL), which binds to RANK on the surface of 
Pre-OC. Inside the joint, RANKL is mainly derived from stromal cells, 
synovial fibroblasts, and Tcells. Osteoprotegerinacts as a decoy receptor for 
RANKL, thereby inhibiting osteoclastogenesis and bone loss.13
CLINICAL FEATURES: 
         Patients often complain of early morning joint stiffness lasting more than 
1hr that eases with physical activity. The earliest involved joints are typically 
the smaller joints of the hands and feet. The initial pattern of joint involvement 
may bemonoarticular, oligoarticular (≤4 joints), or polyarticular (>5 joints), 
usually in symmetric distribution.13
In RA, hands are most commonly affected- wrists, metacarpophalangeal 
(MCP), and proximal interphalangeal (PIP) joints are the most frequently 
involved joints. Flexor tendon tenosynovitis is a common feature of RA and 
leads to decreased range of motion, reduced grip strength and also “trigger” 
fingers. Progressive destruction of the joints and soft tissues may lead to 
chronic, irreversible deformities like “swan neck deformity”, “boutonniere 
deformity” and “Z-line deformity”. Other joints include elbows, knees, feet, 
hips, shoulders and atlantoaxial joints of cervical spine.13,16
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Fig 2: Show comparison of Normal joint, Osteoarthritis & Rheumatoid Arthritis 
joints.
Fig 3: Show Deformities of hand in RA patient.
The following pictures show joint deformities of RA patients who attend the 
Rheumatology OPD Stanley Hospital during this study period
23
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The most common systemic and extraarticular manifestations of RA are 
(i)constitutional symptoms include fatigue, loss of appetite, loss of weight, low 
grade fever, malaise and depression. The other symptoms are (ii) subcutaneous 
nodules, (iii) scleritis, (iv) pleuritis and (v) pericarditis (vi) increased risk of 
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atherosclerosis, (vii) vasculitis and (viii)normochromic normocytic anemia- is 
the most common hematologic abnormality.13
RA patients may experience flareup of symptoms that can last for days to 
weeks, followed by periods of remission.Remission can last for weeks, month, 
or years, during which patients have few or no symptoms. Symptoms reappear 
after a period of remission which is called as relapse. The course of illness 
varies from patient to patient.5,13
Investigations:
The following Investigations were done to make a diagnosis of rheumatoid 
arthritis. 5,13,16
(i) Nonspecific inflammatory markers: ESR & CRP.
            (ii) Rheumatoid factor (RF) – IgM, IgG, IgA isotypes.
            (iii) Antinuclear antibodies (ANA).
            (iv) Joint imaging: Plain x-ray of Affected joint(s)
(v) Synovial fluid analysis – Synovial fluid White blood cell (WBC) counts can 
vary widely, but generally range between 5000-50,000WBC/µL compared to 
<2000WBC/µL for a non-inflammatory condition such as osteoarthritis.
            (vi) Ultrasound and magnetic resonance imaging (MRI)for  joints.
            (vii) Anti-cyclic citrullinated peptide antibodies (ACPA).
The overall mortality rate in RA is two times greater than general population, 
with ischemic heart disease being the most common cause of death followed by 
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infection. 1 The other causes of death in RA are lymphoproliferative disorders 
and gastrointestinal bleeding.15
Pathogenesis of atherosclerosis in RA:
          There is an evidence that persistent, high-grade inflammation present in 
RA is the main cause of development of premature atherosclerosis and its 
complication.15The release of number of proinflammatory mediators from    
inflammation of RA   is associated with accelerated atherosclerotic process17. 
These cytokines not only cause the local inflammation and joint destruction, 
but also affects the vascular system like liver, adipose tissue and vascular 
endothelium resulting in unfavourable, ‘proatherogenic’ state.Inflammatory 
markers of endothelial activation play an important role in cardiovascular risk. 
Chemokines and Endothelial adhesion molecules   are the important factors for 
the release and extravasation of inflammatory cells into the interstitial matrix.17
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ClassificationCriteria for Diagnosis of Rheumatoid Arthritis: 13
Joint
involvement
1 large joint (shoulder, elbow, hip, knee, ankle)    0
2-10 large joints    1
1-3 small joints (MCP, PIP, thumb, IP, MTP, 
wrist)
   2
4-10 small joints.    3
>10 joints (at least 1 small joint)    5
Serology
Negative RF and negative ACPA 0
Low-positive RF or low-positive anti-CCP 
antibodies (≤3times ULN)
  2
High-positive RF or high-positive anti-CCP 
antibodies (>3 times ULN)
3
  Acute-phase 
reactants
Normal CRP and normal ESR   0
Abnormal CRP or abnormal ESR   1
Duration of 
symptoms
<6weeks   0
    ≥6weeks 1
A score of ≥ 6fulfills requirements for definite RA. 
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The prothrombotic factors like “fibrinogen, von Willebrand Factor(vWf) and 
tissue plasminogen activator antigen(tPa)or D-dimer” are also  elevated in these 
patients.21
Fig 12: Shows Release of proinflammatory cytokines from the synovial 
tissue.
(i)Endothelial dysfunction:
      In RA patients the endothelium shows the signs of dysfunction. It has been 
shown that the endothelium-dependent dilatation is impaired in RA patients 
when compared to control.23 It is also evident that the impairment of the 
endothelium is at cellular level. The Endothelial progenitor cells (EPCs) which 
is secreted by hematopoietic system. This EPCs plays an important role in the 
development and maintenance of the endothelial cell layer and very effectively 
repairs the vascular endothelium. This EPCs protect against ischemia and 
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atherosclerosis.24 The number of circulating EPCs was found to correlate 
inversely with the Framingham risk factor score.27
In RA patients this EPCs are reduced in number, which is associated with 
dysfunction of endothelium.28 This reduced number of EPCs is inversely 
correlated with disease activity.29
(ii) Alterations in vascular function:
       In RA patients the function of vascular system is altered. Arterial stiffness 
is the predictor of mortality and cardiovascular risk.30The Pulse wave velocity 
is the marker of arterial stiffness. In RA patients the pulse wave velocity is 
higher than control. That reflecting the arterial stiffness is increased in RA 
patients.31 The “Augmentation index” (AIx) is another marker for vascular 
dysfunction.32 These changes are associated with unfavourable energy 
requirement of heart during systole. As a result, the ejection into the stiffer 
vessels is associated with a higher energy requirement. This will cause 
unfavourable supply/demand relationship of the myocardium.34,35 In RA not 
only the vascular dysfunction of macrovascular system, the microcirculation is 
also affected.36
(iii)Cardiovascular morbidity and mortality:
In RA patients all these changes are associated with increased cardiovascular 
morbidity and mortality22 However, in RA, the cardiovascular risk factors 
aresimilar to diabetes. In a prospective study, for RA  patient and General 
population, the 3-year incidence rate of fatal and nonfatal cardiovascular events 
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was 9.0% and 4.3% respectively.26  In a case of RA the common risk 
calculators for Cardiovascular disease like Framingham under estimate the 
cardiovascular risk. Therefore, it was advisable to use the risk score models by 
a multiplication factor of 1.5 for Cardiovascular morbidity and mortality in 
rheumatoid arthritis patients.37
         In RA patients, the CVS morbidity and mortality meets two of the 
following three criteria 38:
(i) Duration of disease will be >10 years. 
(ii)Rheumatoid factor (RF) and or anti-CCP antibodies are positive.
             (iii) Presence of extra-articular manifestations.
        In RA patients the clinical presentation of cardiovascular disease differ 
from the general population. Douglas and co-workers were found that more 
recurrent cardiac events are present in RA patients than in controls.38
Increased mortality following cardiovascular events- the “30-days 
cardiovascular mortality after a first acute cardiovascular event was 17.6% in 
RA patients vs. 10.8% in non-RA patients”.39
In RA patients, the overall case fatality is higher compared to controls (hazard 
ratio 1.67, 95% CI: 1.02–2.71), and also a shorter survival time after a 
myocardial infarction. These findings are of interest, as similarities are shown 
to be increased cardiovascular risk in patients with type 2 diabetes.40
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Inflammation of RA is related to dyslipidaemia. Total cholesterol (TC) and 
High-density lipoprotein cholesterol (HDL-C) levels are low in RA patients.41
But when the RA patients treated with anti-inflammatory drugs, the lipid levels 
become increased,but there is no change in atherogenic index TC/ HDL-C after 
treatment.42
The association between CV risk and Lp (a) in general population was assessed 
through genetic and Mendelian randomization studies. This strongly point that, 
Lp(a) as important risk factor for the process of atherogenesis43.
LIPOPROTEIN(a):
             Lipoprotein (a) is a particle,it is associated with increased risk of 
premature CHD and stroke20. Lp(a) is nearly identical in structure to an LDL 
particle25.  The distinguishing feature is apo-(a), plasminogen like glycoprotein 
that is linked toapo B100 by disulphide bond.44 The structural gene for apo(a) 
is located on chromosome 6.   Lp(a) particles are heterogenous in both size and 
density, as a result of a differing number of repeating peptide sequences, called 
kringles,in the apo(a) portion of the molecule. Lp(a)is larger than LDL and has 
a higher lipid content and a slightly lower density.20
32
Fig 13:Shows Structure of Lipoprotein (a).
Factors affecting Lp(a):
(1) Genetics- Determine the Circulating levels of Lp(a).
(2) Diet may play some role- trans fatty acids have been shown to 
increase Lp(a).     
(3) Niacin reduces Lp(a) and raises HDL.25
Lp(a) was involved in inflammation and thrombosis 4.Lp(a) was significantly 
associated with acute phase proteins and was found topromote 
proliferation of vascular smooth muscle cells and chemotaxis of human 
monocytes. Its role in atherosclerosis was suggested by the structure of  apo 
(a).45This antifibrinolytic effect is primarily defined by the size of the apo(a) 
polymorphs, which show heterogeneity in their fibrin-binding activity-only 
small size isoforms display high affinity binding to fibrin.44
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PATHOGENESIS OF LIPOPROTEIN(A):
          In Lp(a), the apo(a) exists several isoforms – defined by variable number 
of copies of plasminogen- like kringle 4 and single copies of kringle 5 and the 
catalytic region46. At least one of the plasminogen-likekringle 4 copies present 
in apo(a) (kringle IV type 10) contains a lysine binding site (LBS) that is 
similar to that of plasminogen. This structure allows binding of these proteins 
to fibrin and cell membranes47. 
         Plasminogen thus bound is cleaved at Arg561-Val562 by plasminogen 
activators and transformed into plasmin. This mechanism ensures fibrinolysis 
and pericellular proteolysis49. In apo(a) a Ser-Ile substitution at the Arg-Val 
plasminogen activation cleavage site prevents its transformation into a plasmin-
like enzyme50. Because of this structural/functional homology and enzymatic 
difference, Lp(a) may compete with plasminogen for binding to lysine residues 
and impair fibrinolysis and pericellular proteolysis48.
Kringle domines of Lp(a) have a high level of homology with plasminogen, (a 
precursor of plasmin that promotes clot lysis via fibrin cleavage), it has been 
proposed that Lp(a) may compete with plasminogen for binding sites on 
endothelium and on fibrin, thereby promoting clotting20. 
The Pathogenesis of LP(A) in development of atherosclerosis are:
   (i)  It accumulates in the arterial intimal layer.
(ii) It activates inﬂammatory cells. 
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(iii) Binds to proinﬂammatory-oxidized-phospholipids1.
(iv) It promotes thrombosis and inhibits ﬁbrinolysis due to the high structural 
homology between apo(a) and plasminogen.25
       Lipid contents of the Lp (a) and LDL-C were similar. They might have 
similar mechanisms for development of atherosclerosis. It was suggested that 
in active RA the reticulo-endothelial system was became over stimulated and 
the lipid elimination by scavenger receptors of macrophages was increased. For 
this reason,important atherogenic factor -the LP(a) have vital role8. 
Role of Lipoprotein(a) in atherosclerosis:
Lp(a) is a sticky particle, which binds to glycosaminoglycans, proteoglycans, 
collagen and other connective proteoglycans, collagen and other connective 
tissue structures46.It isimmunochemically related to plasminogen. Plasminogen 
is a zymogen foundinplasma.Upon activation, itforms plasmin which causes 
fibrinolysis.Apo(a) moiety [kringle IV &V repeats]ofLp(a)has about 0% amino 
acid sequence homology to plasminogen47. By different ways, Lp(a) interferes 
with fibrinolytic activity of plasminogen.(i)Because of the structural homology, 
Lp(a) inhibits the binding of plasminogen to it’sreceptor on endothelial cells.  
Thus, the activation of plasminogentoplasminis prevented. 
35
Fig 14: Pathogenesis  Lp(a) in atherosclerosis.
(ii) Lp(a)competes with plasminogen for binding sites on fibrin, 
interferingwiththe action of plasminogenincausingfibrinolysis.
(iii) Lp(a) attaches to lysine residues on fibrin in atherosclerotic 
plaquesinhibitingfibrinolysis.
Lp(a) levels of about 30mg/dL has traditionally been used as an atherogenic 
cutoff, elevated levels of Lp(a) (>30mg/dL) are now known to increase the risk  
ofcardiovascular disease.11
Lipoprotein(a)andCardiovasculardiseaserisk:
            Lipoprotein(a)isamajorindependentgeneticriskfactorfor cardiovascular 
disease.51ElevatedLp(a)levelsassociatedobustlyandspecificallywithincreasedris
k ofcardiovasculardisease.Thisassociationiscontinuousanddoesnotdependon 
thepresenceofotherCVDriskfactors.Lp(a)levels,likeelevatedLDL,iscausallyrelat
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edtoprematuredevelopmentofatherosclerosisandCVD.52
       The concentration of Lp(a) is inversely related to the size of apo(a) 
isoform20. Studieshaveshown thatsubjectswithsmall 
apo(a)phenotypeshaveatwofoldriskofCVDandstrokecomparedwiththosewithlar
gerisoformsofapo(a).53
METABOLISMOFLIPOPROTEINS-ANOVERVIEW:
1.LiverandIntestinalmetabolismofTriglyceriderichApoBcontainingLipopro
teins:53
ApoB-48Chylomicron (CM) particles assembled in the enterocytes 
(exogenouspathway) and ApoB-100 Very low density lipoprotein (VLDL) 
particles produced in the hepatocytes (endogenous pathway) are releasedinto 
thecirculation.These nascent CMandVLDLparticlesacquireApoEand ApoC 
fromHDL particles in circulation and become functionally mature.ApoCII 
activatestheenzymeLipoproteinLipase(LPL),while theApoCIandApoCIII 
haveinhibitory roles.11,20LPLhydrolyzes triglycerides in mature CMandVLDL 
particlesinthe capillaries ofperfused skeletalmuscle andadipose tissue.53 This 
leads to therelease of free fatty acids which are taken up by 
adipocytes/myocytes and CMremnants and VLDL remnants (Intermediate 
densitylipoprotein[IDL]) areformed. CMremnants are removed by the liver via 
LDL receptor related protein(LRP), aftertriglyceride 
andphospholipidsarehydrolyzedbyHepaticLipase(HL)11. 
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Figure 15: Overview of Lipoprotein metabolism.
MostoftheIDLparticlesaresubjectedtofurtherhydrolysisbyHL 
tobecomesLowDensityLipoproteins(LDL).LDL particles aretakenupby the 
LDL receptor. Rest of the IDLparticles are taken up by the LRP. 
VLDLarealsoremovedviatheVLDLreceptorinadipocytes/myocytes.11
2.MetabolismofApoA1andHighDensityLipoprotein:11,54
      The Reverse Cholesterol Transport process operates to remove 
theexcesscholesterol from peripheral tissues via the High density 
lipoproteinstobedisposedintheliver.Thefreecholesterol (FC) effluxes from 
thecell to thesurface of lipid-poor ApoA1 via the ATP-binding cassette 
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transporter1 (ABCA1). Nascent ApoA1 particles becomes mature 
HDLparticlesthroughtheesterification offrecholesteroltocholesteryl-
esters(CE)bytheenzymeLecithin-Cholesteryl Acyl Transferase (LCAT).
Fig 16: Shows Metabolism of HDL:
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CE-richHDLparticlesenterthe circulation11.Thesearethen, taken updirectly by 
the liverthrough Hepatic Scavenger Receptor (SR-B1) orindirectlyafter 
exchange of Cholesteryl Esters inHDL for Triglycerides inApoBcontaining 
lipoproteins (LDL, VLDL, 
CM,IDL)byCholesterylEsterTransferProtein(CETP).55
Carotid Artery Doppler:
Subclinical atherosclerosis can also be demonstrated by increased carotid artery 
intima media thickness (IMT)56. In patients with high cardiovascular 
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risk, it is important to identify the vascular injury early. The carotid artery 
intima-media thickness (IMT), measured by ultrasound, has been established as 
a valid marker for early atherosclerosis58.The cIMT measured by ultrasound is 
a surrogate marker of atherosclerosis and it is the most widely used 
noninvasive imaging method to assess CVD risk and atherosclerosis57.
Intima–media thickness (IMT), also called intimal medial thickness. It is 
a measurement of the thickness of tunica intima and tunica media- the 
innermost two layers of the wall of an artery. The measurement is usually made
by external ultrasound .59
Ultrasound IMT measurement was first proposed and validated in 
vitro by Paolo Pignoli in 1984.60. However, in 2003 the European society of 
Hypertension -guidelines for the management of arterial hypertension 
recommended the use of IMT measurements in high-risk patients to help 
identify target organ damage.61
Carotid intima media thickness (IMT) is a doppler measurement of carotid 
artery, that measures the intima media layers- where the atheroma begins. It is 
considered as a good marker of atherosclerosis in its initial stage.62Among the 
various screening methods the carotid intima media thickness (CIMT) has 
gained wide acceptance  marker of atherosclerosis, predicting future 
cardiovascular events63. CIMT is a easy, non-invasive, reliable and relatively 
inexpensive tool for screening  atherosclerosis.64
Fig 17 : Show the Structure of an Artery wall
The associations between 
Growing evidence has demonstrated that, patients with RA have a higher risk 
for atherosclerosis66,67. RA patients are associated with enhanced CV risk and 
subclinical vascular disorder
confirmed that RA is associated with increased CIMT 
The mechanisms of RA
Ox-LDL69, vWF activity
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cIMT and rheumatoid arthritis (RA)
65. Recent quantities clinical observ
68. 
-related CIM thickening included increased levels of 
70, serum mannose-binding lectin71 as well as
ations have 
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Fig 18: shows normal ultrasonic examination of Carotid IMT 
increased levels of inflammation markers such as IL-17 and CRP 72 and lower 
levels of carotene70, vitamin D, CD34+ cells71 and NO72 and may increase the 
burden of subclinical atherosclerosis73. Their mechanisms involved elevated 
myeloperoxidase levels in juvenile idiopathic arthritis74, circulating levels of 
OxLDL.IMT is used to detect the presence of atherosclerosis in humans and 
more contentiously  to track the regression  arrest or progression of 
atherosclerosis.75
                                   Measure of IMT
IMT can be measured by using external ultrasound in large arteries relatively 
close to the skin (e.g. the carotid, brachial, radial, or femoral arteries). External 
ultrasound methods have the advantage of being comparatively lowcost and 
non-invasive and also convenient to the patients.
Deeper internal arteries, such as the coronary arteries require special 
intravascular catheters employing ultrasound or optical coherence tomography
to measure IMT.76
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External ultrasound methods have the advantage of being comparatively low 
cost and  non-invasive and also convenient to the patients. Deeper internal 
arteries, such as the coronary arteries require special intravascular catheters 
employing ultrasound or optical coherence tomography to measure IMT.76
        The carotid artery is the usual site of measurement of IMT and consensus 
statements for carotid IMT have been published for adults77 and children.78
Often, IMT is measured in three locations: in the common carotid artery 
(typically at one cm proximal to the flow divider), at the bifurcation, and in the 
internal carotid artery.80 IMT measurements of the far (deeper) wall, by 
ultrasound, are generally considered more reliable than measurements 
performed on the near (more superficial) wall;79 although measurement of both 
near and far wall IMT has also been advocated.82
Carotid IMT has been used in many epidemiological and clinical studies and 
these have shown associations with several risk factors including type-2 DM, 
familial hypercholesterolemia, High Density Lipoprotein- Cholesterol (HDL-
C), triglycerides,81rheumatoid arthritis,83non-alcoholic fatty liver disease.84
Since the 1990s, some clinical trials of lifestyle Carotid IMT has been used in 
many epidemiological and clinical studies and these have shown associations 
with several risk factors including type-2 DM, familial hypercholesterolemia, 
High Density Lipoprotein- Cholesterol (HDL-C), triglycerides,81rheumatoid 
arthritis and pharmaceutical interventions have also used carotid artery IMT as 
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a surrogate marker for evaluating the regression and/or progression of 
atherosclerotic cardiovascular disease.85
    Fig 19(a)                                                    Fig 19(b)
Fig 19:show Ultrasonographic examination of Carotid IMT (distance from 
arrows) at the wall of common carotid artery.  (a) Normal Carotid IMT. 
(b) Increased Carotid IMT.
          Although carotid intima-media thickness is strongly associated with 
atherosclerosis. Intima-medial thickening is a complex process, depending on a 
variety of factors, including blood pressure, local hemodynamic,shear stress 
and circumferential tensile stress.86
Variations in IMT between different locations (e.g. the common carotid 
artery, the carotid bulb and the internal carotid artery) may reflect difference in
local hemodynamic forces. Ultrasound measurement  of carotid intima 
mediathickness could be recommended to the majority of RA patients, 
especially in patients classified in the high CV risk group , patients with extra-
articular manifestations and RF or anti-CCP antibodies positivity or 10-year 
disease   progression.87
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The purpose of our present study was to measuring Carotid IMT and 
Carotid plaques by using high resolution B-mode ultrasound and colour 
doppler to assess the existence of subclinical atherosclerosis in RA patients and 
healthy controls.10
          Hence, we measure   fasting serum lipoprotein (a), lipid profile and to 
measure the carotid artery intima media thickness in RA patients and control 
groups.     
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AIM:
To Evaluate the association of Serum Fasting Lipoprotein (a) and  lipid profile 
& Carotid Intima Media Thickness in Rheumatoid Arthritis patients in 
prediction of Cardiovascular Risk. 
OBJECTIVES: 
      1.To estimate Fasting Lipid Profile & serum Lipoprotein(a) in Controls and 
Rheumatoid Arthritis patients.
      2.To measure the Carotid intima media thickness and Carotid plaques on 
both Right and left sides.
      3.To correlate Serum Lipoprotein(a) levels with Fasting Lipid Profile in RA 
patients.
      4.To correlate Serum Lipoprotein(a) levels with Carotid intima media 
thickness in Rheumatoid Arthritis patients. 
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MATERIALS AND METHODS:
STUDY PLACE:
Government Stanley medical college & Hospital, Chennai-01. 
         1.Department of Biochemistry 
        2. Department of Rheumatology
        3. Department of Radiology 
4.Department of Community medicine
Study Design: 
         Case control study.
Study Population:
Sero-positive rheumatoid arthritis patients of both genders in the age group 
between 25 and 70 years are considered as case from rheumatology OP.                                 
          Age and sex matched without rheumatoid arthritis are considered as 
controls.
Sample size: 
         Case -50. Sero positive, 25-70 years of Rheumatoid Arthritis patients.
         Control- 50.  Age & Sex matched Healthy subjects taken as controls.
Inclusion criteria: 
         Male and female patients who were diagnosed with rheumatoid arthritis.
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Exclusion criteria:
      1.Patients with Hypertension, diabetes mellitus and clinically manifest 
atherosclerosis by way of coronary artery disease, peripheral vascular disease 
and cerebrovascular disease.
      2.Patients known to have dyslipidemia of any aetiology and on treatment.
      3. Past History of systemic disease like pulmonary disorder, thyroid 
disorder, Liver disorder, etc.
      4. Age group under 18 years.
     5.History of smoking and alcoholism.
Study duration:
         December 2017 – July 2018.
METHODS:
Study procedure:
After obtaining institutional ethical committee clearance, the study was started. 
The purpose of the study and study procedure was explained to the RA patients 
and control groups with their native language. Informed consent was obtained 
in both cases and controls. After taking detailed clinical history taking and 
General &Systemic examination I filled the clinical proforma and the fasting 
blood samples were collected and the carotid artery doppler was done on the 
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same day. Fasting lipid profile &Lp(a) levels were estimated and Carotid 
Intima Media Thickness & Carotid plaques were measured.
     Test results were recorded and data was analysed by standard statistical 
methods.
Sample Collection and Preparation: 
After getting informed consent from the patient, 10-12 hours fasting morning 
blood sample was collected under strict aseptic precautions in a plain red 
topped venepuncture tubes without any additives or gel barrier. Samples are 
allowed to clot for 20-30 minutes and centrifuged at 2000-2500 rpm for 
15minutes. Serum was separated immediately and aliquoted into 2 Eppendorf’s 
-one aliquot was used for to measure Serum Lipid profile. Other aliquot was 
stored at -200C in deep freezer for estimation of Serum Lipoprotein(a). 
Lipoprotein (a) levels were stable up to 3months if the serum is stored at -200C.
                  Study population were examined and following estimationswere 
done in serum samples:
(i)  Lipoprotein(a).
(ii) Fasting Lipid profile:
         (a)Serum Total Cholesterol(TC)
         (b)Serum Triglycerides (TGL)
         (c)Serum HDL(HDL)
(d)Serum LDL:  calculated using Friedewald equation:
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                   LDL = Total Cholesterol – (HDL + Triglyceride/5)
          (e) Serum VLDL = TGL / 5
          (f)Non HDL = Total Cholesterol – HDL.
Tests are assayed using kits by fully automated Beckman Coulter AU 480, after
Calibration and internal quality control was done.
(iii)CAROTID ARTERY DOPPLER:
         Carotid artery intimal and medial thickness measured by color doppler 
ultrasonography using high frequency linear probe.
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METHODS
ESTIMATIONOFSERUMTOTALCHOLESTEROL:11
Method:
Enzymatic Colorimetric: Cholesterol oxidase
       CHOD–PAP method.
Principle:
Step1:
Cholesterolesters+H2O       CholesterolesteraseFattyAcids + Cholesterol
Step2:
         Cholesterol+  O2     CholesteroloxidaseCholest-4-en-3-one+H2O2
Step3:
          2H2O2+4-Aminoantipyrine+Phenol PeroxidaseQuinoneiminedye+4H2O
The intensity of the pink colour due to quinoneimine dye formed, is 
DirectlyProportional to Cholesterol concentration.
REAGENT COMPOSITION:
Goods Buffer (pH–6.4):100mmol/L
Cholesterol oxidase:>100U/L
Cholesterol esterase:>200U/L
Peroxidase:>3000U/L
4-Amino antipyrine:0.3mmol/L
Phenol:5mmol/L
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SYSTEM PARAMETERS:
Mode EndPoint
Wavelength1 505nm
Wavelength2 670nm
SampleVolume 10µL
ReagentVolume 1000µL
Incubationtime 5minutes
IncubationTemperature 37°C
NormalLow 50mg/dL
NormalHigh 230mg/dL
Linearity 750mg/dL
Standardconcentration 200mg/dL
Absorbancelimit 0.4
Blankwith Reagent
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ASSAY PROCEDURE:
Blank Standard Sample
Reagent 300µL 300µL 300µL
Distilled water 3µL - -
Standard - 3µL -
Sample - - 3µL
Mix well and incubate for 5minutes at 37°C.Read the absorbance of the Test(T)  
and  standard (S)againstreagentblank at 505nm or Green filter.
Tests were assayed on Beckman Coulter AU 480 autoanalyser afterCalibration.
CALCULATION:
Cholesterol concentration(mg/dL)=AbsorbanceofTest x Std.con (200mg/dL)
Absorbance of Standard
Referenceintervals:11,2
Adults
       SerumTotalCholesterol: Desirable:<200mg/dL
                                                BorderlineHigh:200-239mg/dL
                                                 High:>239mg/dL
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ESTIMATION OF SERUM TRIGLYCERIDES:
Method:Enzymatic Colorimetric:
Glycero-3-phosphateoxidasemethod
GPO-TOPS
Principle:
Step1:
Lipasecatalyzed hydrolysisoftriglyceridestoglycerolandfreefattyacids.
           Triglyceride+3H2OLipaseGlycerol+3Fattyacids
Step2:
          GlycerokinasephosphorylatestheglycerolinanATP-requiringreaction.
       Glycerol+ATPGlycerokinaseGlycerol-3-phosphate+ADP
Step3:
          Glycerophosphateoxidase(GPO)oxidizesGlycerol-3-phosphateto
DihydroxyacetonephosphateandH2O2.
       Glycerol-3-phosphateGPO    Dihydroxyacetonephosphate+H2O2+O2
Step4:
          
H2O2formedismeasuredinaperoxidasecatalyzedreactionthatformsacoloreddye
2H2O2+4-Aminoantipyrine+TOPS   Peroxidase     Quinoneiminedye+4H2O
Theintensityofthecolourduetoquinoneiminedyeformed,isdirectly
ProportionaltoTriglycerideconcentration.
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REAGENTCOMPOSITION:
PipesBuffer(pH–7.0):5mmol/L
TOPS:5.3mmol/L
PotassiumFerrocyanate:10mmol/L
Magnesiumsalt:17mmol/L
4-Aminoantipyrine:0.9mmol/L
ATP:3.15mmol/L
Lipoproteinlipase:>1800U/L
Glycerol kinase:>450U/L
Glycerol-3-phosphate oxidase:>3500U/L
Peroxidase:>450U/L
TOPS:N-Ethyl-N-sulfopropyl-m-toluidine
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SYSTEM PARAMETERS:
Mode of reaction EndPoint
Slope of reaction Increasing
Wave length1 546nm(540-560nm)
Wave length2 630nm
Temperature 37°C
Standard concentration 200mg/dL
Linearity 1000mg/dL
Blank with Reagent
Incubation time 5minutes
ample volume 10µL
Reagent volume 1000µL
Cuvette 1 cm light path
ASSAY PROCEDURE:
Blank Standard Sample
Reagent 300µL 300µL 300µL
Distilled water 3µL - -
Standard - 3µL -
Sample - - 3µL
56
Mixwellandincubate it for5minutesat 
37°C.Readtheabsorbanceofthetestsampleandstandardagainstreagentblank.Tests
wereassayedonBeckmanCoulterAU480autoanalyseraftercalibration.
CALCULATION:
Triglyceride concentration (mg/dL)=Absorbance of Test×Stdconc.mg/dl
Absorbance of Standard
Reference interval:11,20
Adults :Desirable:<150mg/dL
Male:60-165mg/dLFemale:40-140mg/dL
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ESTIMATION OF SERUM HDL CHOLESTEROL:
Method:
DirectHomogenousAssay
Principle:
The Cholesterol from low density lipoproteins (LDL), very low density 
lipoprotein(VLDL) and chylomicrons (CM)is brokendown by the 
cholesteroloxidase(CHOD) in an enzymatic accelerated non-color 
forming reaction. The detergent present in the reagent B, solubilizes 
cholesterol from High density lipoproteins(HDL) in the sample.The 
HDL cholesterol is then spectrophotometrically measured by means of 
the coupled reactions.
Step 1:
Cholesterol esters +H2O  chol. esterase   Cholesterol + Fatty acid
Step 2:
     Cholesterol + ½ O2      chol.oxidase         Cholesternone +H2O2
Step3:
2H2O2+4-Aminoantipyrine+TODB    Peroxidase  Quinoneimine + 4H2O
(λmax=560nm)
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REAGENTCOMPOSITION:
R1Reagent:Good’s Buffer, cholesterol esterase, cholesterol oxidase, 
peroxidas,N,N-bis(4-sulfobutyl)-m-toluidine.
ASSAYPROCEDURE:
4µLofsample+300µLofReagent1
Incubatefor5minutesat37°C
Measureabsorbance1bichromaticallyat660/546nm
Add100µLofReagent2
Incubatefor5minutesat37°C
MeasureAbsorbance2bichromaticallyat660/546nm
Calculate HDL concentration by using                                                                             
ΔAbsorbance = Absorbance 1 -Absorbance 2
OtherAssayParameters:
Standardconcentration:49mg/dL
Linearity:200mg/dL
Blankwith:Reagent
Reagentblankabsorbance:<0.05
Cuvette:1cmlightpath
TestswereassayedonBeckmanCoulterAU480autoanalyserafterCalibratio
n.
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CALCULATION:
HDLconcentration(mg/dL)=ΔAbsorbanceofsample×Std conc.mg/dl
ΔAbsorbanceofstandard
Reference intervals:11,20
Adults
SerumHDL:40-60mg/dL
DETERMINATIONOFSERUMLIPOPROTEIN(a):
Method:
    Immunoturbidimetry
Principle:
Latexparticlescoated with 
antiLp(a)antibodiesagglutinatewithLp(a)insamples.Thisagglutinationcausesach
angeinabsorbance,dependingontheLp(a)contentinthesample,whichisquantifiedb
ycomparingwithacalibratorofknownLp(a)concentration.
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REAGENTS:
ReagentR1:
        Glycinebuffer(pH-8.3):50mmol/L
ReagentR2 :
         Glycinebuffer(pH-8.2)
          Latexparticlescoatedwithanti-humanLipoprotein(a) antibody (rabbit)
Sodiumazide:0.9g/L- as preservative.
System parameters:
Reactiontype Ascending
Wavelength 700nm
Blankwith Distilledwater
Samplevolume 7µL
Reagentvolume 500µL
Delaytime 10seconds
Readtime 240seconds
Linearity 90mg/dL
CALIBRATOR:
TheCalibratorisalyophilizedserumofhumanorigincontainingLp(a)ofknowncon
centrationof96.6mg/dL,afterreconstitutionwith1mLNaCl9g/L.ThefollowingLp
(a)calibratordilutionsinNaCl9g/Lwereprepared.The 
Mode Multi-PointCal.
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concentrationofeachoftheLp(a)calibratorswasobtainedbymultiplyingtheLp(a)c
oncentration–96.6mg/dLbythecorrespondingfactor.
Calibratordilution 1 2 3 4 5
Lp(a)Calibrator(µL) - 25 50 75 100
NaCl9g/L(µL) 100 75 50 25 -
Factor 0 0.25 0.5 0.75 1.0
ConcentrationofLp(a)
Calibratordilution(mg/dL)
0 24.15 48.30 72.45 96.60
ASSAYPROCEDURE:
Thereagentsarebroughttotemperatureof37°C.
Blank Calibrator Sample
Distilledwater 7.5µL - -
ReagentR1     300 µL 300µL 300µL
ReagentR2     150µL 150µL 150µL
Calibrator 7.5µL -
Sample - 7.5µL
Mixandreadtheabsorbance(A1)with  in 30sec, incubate for 5minutes 
then read  absorbance(A2)
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CALIBRATIONREPORT:
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Quality control:
Quality control pool values are within the established ranges.
RADOX InternalQualityControlforImmunologicalassays
Mean:32.5Standarddeviation:1.38
CoefficientofVariation:10.35%Range:30to49.09mg/dL
CALCULATIONS:
               The absorbance differences (A2 – A1) of each Lp(a) calibrator Was 
calculated and the values obtained against the corresponding Lp(a) 
concentrations were plotted in a calibration curve.
Lp(a)concentrationinthesamplewascalculatedbyinterpolationofit’s(A2-
A1)inthecalibrationcurve.
Reference interval:11,20
SerumLp(a):
            Desirablecut-off:<30mg/dL.
CALCULATIONS:
Theabsorbancedifferences(A2-
A1)ofeachLp(a)calibratorwascalculatedandthevaluesobtainedagainstthecorresp
ondingLp(a)concentrationwere  
plottedinacalibrationcurve.Lp(a)concentrationinthesamplewascalculatedbyinter
polationofit’s(A2-A1)in the calibration curve.
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Reference interval:11,20
SerumLp(a):
            Desirablecut-off:<30mg/dL.
CAROTID ARTERY DOPPLER:
Patient was placed on supine position, with the head turned away from the 
sonographer. The common carotid artery on both sides  were carefully 
examined for wall changes in all subjects, obtaining different longitudinal and 
transverse views with the high-resolution B-mode ultrasound equipment 
Samsung Accuvix X-G equipped by liner probe (7.5 10 Hz). A region about 
1.5cm proximal to the carotid bifurcation was identified, and the intima media 
thickness (IMT) of the far wall was evaluated as the distance between the 
luminal-intimal interface and the medial adventitial interface.      
All ultrasound measurements were performed by the same examiner who was 
unaware of subject characteristics. This evaluation aims to determine the intima 
media thickness (IMT) and to detect carotid plaques. The mean IMT (the mean 
of both right and left sides) was assessed. At the same time the maximum IMT 
(the highest value either right or left) was also assessed. 
        IMT is considered abnormal if >0.07cm.88
         Plaques were defined as focal widening relative to adjacent segments, 
with protrusion in to the lumen of calcified or noncalcified material.
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RESULTS AND STATISTICAL ANALYSIS
            This study was done to evaluate  fasting Serum lipoprotein(a), lipid 
profile levels and  right &left side carotid IMT measurement was done in total 
of 100 subjects, of which 50 with known RA were taken as cases and 50 
individuals without RA were taken as controls. 
STATISTICAL ANALYSIS
            Results of clinical and biochemical profile obtained in patients with 
Rheumatoid Arthritis disease were compared with those of the control group by 
statistical analysis using Excel software.  Student’s unpaired ‘t’ test was used to 
compare the means between two independent groups. F test was applied 
between the study variables to know whether ‘t’ test can be applied to study the 
parameters and also which type of ‘t’ test -either equal variance or separate 
variance unpaired ‘t’ test can be applied in this study.
Pearson coefficient of correlation was used to estimate the degree of 
association between two quantitative variables. A p-value of <0.05 will be 
considered as statistically significant.
66
Table 1:Age distribution between Study Population.
Parameter
                   Mean ± SD
Controls             Cases
(n=50)   (n=50)
    ‘P’ Value
   Age     44.7 ± 8.4   47.0 ± 9.1   0.19
Table 1: Shows Age distribution into study group and control group. It 
shows no significant difference in age between two groups. This study 
groups are comparable.
67
Table 2: Gender distribution among Control & RA subjects.
Gender Control Case
Females 46 (92%) 47 (94%)
Males 4 (8%) 3 (6%)
Total 50 (100%) 50 (100%)
Graph 1: Gender distribution among Control group & RA Subjects.
Graph 1& Table 2: Shows the gender distribution among RA subjects and 
controls. In our study, 94% of RA were females & 6% were malesand in 
healthy controls 92% of them were females & 8% were males.
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Table 3: Comparison of Lipid profile Parameters between Controls and 
RA subjects.
Fasting Lipid 
Profile 
Parameters
              Mean ± SD
Controls            Cases 
(n=50)               (n=50)     ‘P’ Value
Total 
Cholesterol 
(mg / dL)
  175±32.1 174 ±27.8
0.90
Triglycerides 
(mg/dL)
   112 ±31.0   121 ± 33.4     0.21
VLDL 
(mg/dL)
    24± 8.5     23 ±6.7     0.93
LDL (mg/dL)     106±23.6   111±30.8     0.40
HDL (mg/dL)      46±11.1     45±9.2     0.69
Non HDL
    (mg/dL)     131±26 130±33    0.88
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Graph 2: Comparison of Total Cholesterol, Triglycerides, VLDL 
values between Controls and RA subjects.
Graph 3: Comparison of LDL, HDL &NonHDL values between 
controls and RA subjects.
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Table 3 & Graph 2,3: Shows that the comparison of lipid profile 
variables between controls and RA subjects. These data shows there is no 
statistically significant difference in Total Cholesterol, Triglycerides, 
VLDL, LDL, HDL, Non HDL values between controls and RA subjects.
Table 4: Comparison of Lipoprotein (a) levels between control and RA 
subjects.
٭٭ *Statistically significant
Parameter
              Mean ± SD
Controls            Cases 
(n=50)                (n=50)
    ‘P’ Value
Lp(a)         
(mg / dL)
       
17.3±11.0
32.6 ±17 <0.0001٭٭*
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Graph 4: Comparison of Lp(a) value between control and RA 
subjects.
Table 4 & Graph 4: Shows that, the comparison of Lipoprotein(a) 
between Controls and RA subjects. These data show statistically 
significant (p<0.0001) difference between RA patients and control groups 
in Lp(a) values between controls and RA subjects.
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Table 5: Comparison of Carotid IMT Right and Left side of control 
and RA subjects.
٭**Statistically significant.
Graph 5: Comparison of Carotid IMT Right and Left side of Control 
and RA subjects.
Measurement
            Mean ± SD
Controls     Cases 
(n=50)                (n=50)
    ‘P’ Value
IMT Right
     (mm)
    0.36±0.1 0.54± 0.14 <0.0001***
IMT Left   
      (mm)
0.39 ± 0.1 0.52 ± 0.13 <0.0001***
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Table 5 & Graph 5: Show the comparison of Carotid IMT of Right & Left 
sides between controls and RA subjects. The data demonstrate that
statisticallysignificant (p<0.0001)differences in the values of Carotid IMT of 
both sides between controls and RA subjects.
Table 6: Pearson’s correlation between Serum Lp(a) and Lipid 
profile in RA patients.
S.No       Analytes
Pearson’s 
correlation 
coefficient 
(‘r’ value)
      Significance
1. Lp(a) Vs TC    0.212 Weak correlation
2. Lp(a) Vs TGL    0.021 No correlation
3. Lp(a) Vs LDL      0.361 Moderate
correlation
4. Lp(a) Vs HDL     0.066 No correlation
5. Lp(a) Vs VLDL     0.015 No correlation
Table 6. Explain the Pearson’s Correlation Coefficient between Lp(a) 
and lipid profile in RA patients. It revealed moderate positive correlation 
between Serum Lp(a) andLDL(r=0.361). A weaker positive correlation is 
observed between serum Lp(a) and Total 
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cholesterol(r=0.212).Nocorrelation between serum Lp(a) and TGL 
(r=0.021), VLDL(0.015)and HDL (0.066).
r value = >0.7 Strong correlation.
r value = 0.3 to 0.7 Moderate correlation.
r value = < 0.3 Weak correlation.
r value = 0 – <0.1 No correlation.
Table 7: Pearson’s correlation between Serum Lp(a) and Carotid
IMT in RA patients.
S.No       Analytes
Pearson’s 
correlation 
coefficient 
(‘r’ value)
      Significance
1. Lp(a )Vs IMT-Right    0.897   Positive 
correlation
2. Lp(a) Vs IMT-Left    0.805 Positive 
correlation
Table 7:Explain the Pearson’s Correlation CoefficientbetweenLp(a) and 
Carotid IMT of right and left sides in RA patients. It demonstrates that a 
strong positive correlation between Serum Lp(a) and IMT-Right 
(r=0.897) &IMT-Left (r=0.805) sides of carotid artery.
Graph 6: Regression analysis between Lp(a) levels and Carotid IMT 
on right side in RA subjects. 
r square = 0.7984
Graph 6 explains the correlation of Serum Lp(a) levels and Carotid IMT 
on right side among RA subjects. Linear regression analysis has an 
upward slope suggesting that Right side Carotid IMT values have strong 
positive correlation (r=0.897) with Serum Lp(a) levels
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.
Graph 7: Regression analysis between Lp(a) levels and Carotid IMT 
on left side in RA subjects. 
r square = 0.6465
  y=0.006258٭X +0.3107
Graph 7 explains the linear regression analysis between Serum Lp(a) 
levels and Carotid IMT on left side, this demonstrate that the Carotid 
IMT-Left have a strong positive correlation(r=0.805) with serum Lp(a) 
levels and linear regression analysis has an upward sl
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ope.
Graph 8: Regression analysis between Serum Lp(a) and Total 
Cholesterol levels in RA subjects. 
r square = 0.08207
y = 0.5586٭X + 158.4
Graph 8 explains the linear regression analysis between Serum Lp(a) and 
Total cholesterol levels, demonstrate that the  Serum Total cholesterol 
levels have a weak positive correlation (r=0.212) with serum Lp(a) levels
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.
Graph 9: Regression analysis between Serum Lp(a) and LDL levels 
in RA subjects. 
r square= 0.06675
y=0.4828٭X+94.64
Graph 9 explains the linear regression analysis between Serum Lp(a) 
and LDL level, demonstrate that the  Serum LDL levels have a moderate 
positive correlation (r=0.361) with serum Lp(a) levels and linear 
regression analysis has an  upward slope.
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Graph 10: Regression analysis between Serum Lp(a) and TGL levels 
in RA subjects. 
r square=0.000255
  y=0.01206٭X+112.3
Graph 10 explains the linear regression analysis between Serum Lp(a) 
and TGL levels, this demonstrate
correlation(r=0.021) with serum Lp(a) levels.
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s that the Serum TGL has a no
Graph 11: Regression analysis between Serum Lp(a) and 
in RA subjects. 
r square=0.006711
y=0.04602٭X+94.64
Graph 11 explains the linear regression analysis between Serum Lp(a) 
and HDL levels, demonstrate that the 
correlation (r=0.066) with serum Lp(a) levels
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H
serum HDL levels have a 
.
DL levels 
no
Graph 12: Regression analysis between Serum Lp(a) and VLDL 
levels in RA subjects. 
r square = 0.0003113
y = 0.009110٭X +23.06
Graph 12 explains the linear regression analysis between Serum Lp(a) 
and VLDL levels, this demonstrate that the Serum 
correlation(r=0.015) with serum Lp(a) levels.
Graph 13: Regression analysis between Serum Lp(a) and RA 
Age. 
r square =0.07253
y=0.1313٭X+42.66
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VLDL have a no
patients 
Graph 13: Explains correlation of serum Lp(a) values and age of the 
patients. Serum Lp(a) values have positive correlation
Age of the patients.
Graph 14: Regression analysis between 
Lipoprotein (a).
r square = 0.3661
y=0.1386٭ X+42.66                                                                                                                      
Graph 14: Explains correlation of Lp(a) with Duration of R
values have moderate
rheumatoid arthritis.
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(r=0.2526)
Duration of disease 
positive correlation(r=0.5994) with duration of 
with 
RA and 
A. Lp(a) 
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Table 8: Pearson’s correlation between Age of RA patients and 
carotid IMT on right and left sides.
S.No       Analytes
Pearson’s 
correlation 
coefficient
(‘r’ value)
      Significance
1. Age Vs IMT-Right    0.3143   Positive 
correlation
2. Age Vs IMT-Left    0.219 Positive 
correlation
Table 8:Explain the Pearson’s Correlation Coefficientbetween Age and 
Carotid IMT of right and left sides in RA patients. It demonstrates that a 
weak positive correlation between age and IMT-Right (r=0.314) &IMT-
Left (r=0.219) sides of carotid artery.
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Table 9: Pearson’s correlation between Duration of RA and carotid 
IMT on right and left sides.
S.No       Analytes
Pearson’s 
correlation 
coefficient 
(‘r’ value)
Significance
1. Duration Vs IMT-Right    0.4599 Positive correlation
2. Duration Vs IMT-Left    0.4734 Positivecorrelation
Table 9:Explain the Pearson’s Correlation Coefficientbetween Duration
and Carotid IMT of right and left sides in RA patients. It demonstrates
that a moderate positive correlation between duration of disease and IMT-
Right (r=0.4599) &IMT-Left (r=0.4734) sides of carotid artery.
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DISCUSSION
RA patients are more prone to develop atherosclerosis. There is an necessity 
for highly sensitive biomarkers for the early detection of CVD in RA since 
there are fewer diagnostic tools are available to identify the cardiovascular risk 
in RA patients.
                  The present study evaluates the cardiovascular risk in RA patients 
by estimation of Lp(a) level and finds its association with carotid Intima Media 
Thickness and also to evaluate the association between serum Lipoprotein (a) 
and lipid profile among subjects with RA and compare the findings with those 
of healthy control subjects. Adhering strictly to the inclusion and exclusion 
criteria, 50 cases of Rheumatoid Arthritis and 50 apparently healthy control 
subjects participated in this study.
            The mean age distribution in RA population was 47.0 ± 9.1years which 
was more or less similar to the mean age distribution in controls was 44.7± 8.4 
years. There was no statistically significant difference in age among cases and 
controls and hence both the groups are comparable.
             The sex distribution in the study groups included predominant female 
subjects which proves that RA is common in women89. In RA group, 47 were 
females & 3 were males and in control group there were 46 females & 4 males. 
There was no observed difference in sex distribution between RA patients and 
controls group.
86
Controls did not meet the classification criteria for RA or any other 
inflammatory disease. Control subjects were frequently matched for age and 
sex with the entire group of RA patients so as to ensure that the control group 
would not differ markedly from RA groups.
In our study, we did not get a significant difference in serum Total Cholesterol 
[p value:0.90], Serum TGL [p:0.21], LDL [p value:0.85] and VLDL [p 
value:0.93]. This is in concordance with studies done by Govindan et al4 and 
RawhyaR.Elsheroof et al6. This might be due to use of DMARDs which lower 
the cholesterol synthesis90.  Another reason for getting this result was low 
number of sample size.        
              In this study, we also observed no statistically significant difference in 
HDL [p levels :0.69], between cases and controls. This is in accordance with 
findings of RawhyaR.Elsheroof et al6 and Angelile et al8. 
           In our study, a statistically significant difference was observed in serum 
Lipoprotein (a) levels (p value <0.05) between RA patients (32.6 ± 17 mg/dL) 
and controls (17.3 ± 11.0 mg/dL). This result is concordance with Rantapaa-
Dahlquvis et all and Dursunoğlu D15 et all who also found the similar results in 
his study. In RA patient serum Lp(a) levels ranges from 10mg/dL to 89mg/dL 
& in controls ranges from 4.7 mg/dL to 72 mg/dL. The effect of the 
inflammatory process on Lp(a) metabolism are unclear. 
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It was suggested that increased synthesis and /or decreased destruction of Lp(a) 
or changes in Lp(a) distribution between intravascular and extravascular 
regions may cause dyslipoproteinemia in RA92.
As an increased concentration of Lp(a) was an important cause of 
cardiovascular disease in patients with rheumatoid arthritis. Lp(a) is an 
independent risk factor for CVD in RA patients because Lipoprotein (a) shares 
structural homology with plasminogen and plasmin. It has potentially 
prothrombotic and anti-fibrinolytic properties. This could promote clot 
stabilization and thrombosis.93
       The present study revealed increase level of carotid IMT in RA patients 
(Right side is 0.54± 0.14mm & Left side is 0.52 ±0.13mm) when compared to 
controls (Right side is 0.36 ± 0.1mm & Left side is 0.39±0.1mm) which is 
statistically significant (p value<0.05). This finding is consistent withmCarotti 
and salaffi et al10 studies.  Current study results revealed that right sided carotid 
artery is thicker than left side in RA patients. In control groups left side carotid 
artery is thicker than right side. Carotid Plaques were also more frequently 
observed in RA patients. In our study, the cut-off point of IMT is considered 
abnormal if >0.07cm which was in agreementwith Elshereef RR, 
Darwish et al6.
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The current study revealed a strong positive correlation between Serum 
Lipoprotein(a) and Carotid Intima Media Thickness (r=0.897 on right side & 
r=0.805 on left side) in RA subjects.It indicates that serum Lipoprotein (a) 
levels are increased as the values of carotid intima media thickness are 
increased. This result is in concordance with Arpita basu et al who also found 
same significant correlation between Lipoprotein(a) and carotid IMT in Type-1 
DM population.2
The present study shows a moderate Positive correlation between Serum 
Lipoprotein(a) and LDL (r=0.361) in RA subjectsThe present study revealed 
Weak Positive correlation between Serum Lipoprotein(a) and Total 
Cholesterol(r=0.212)in RA subjects. 
         In this study no correlation was found between serum Lp(a) and 
TGL(r=0.021), VLDL(r=0.015) and HDL (r=0.066) levels in RA subjects. This 
finding is in accordance with Shiva Govindan et al4. 
          This study also revealed the weak positive correlation between age of 
RA patient and serum Lp(a) levels (r= 0.2526). Lp(a) levels are not dependent 
on age of the patient.   
          Thepresent study revealed a moderate Positive correlation between 
Serum Lipoprotein(a) and duration of RA disease (r=0.5994). This finding is 
observed with Park Y B et al66 and Dursunoğlu D15studies,indicates that 
duration of disease increased, the serum Lp(a) levels also increased.
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This study revealed positive correlation between duration of disease and carotid 
IMT. When duration of disease increased carotid IMT also increased.This 
finding is observed with Park Y B et al66 studies.
Estimation of serum Lipoprotein(a) is better than lipid profile in early detection 
of CV risk in RA patients. Increased serum Lp(a) value show good correlation 
with Carotid Intima Media Thickness in RA patients. 
Duration of disease has good correlation with increased level of lipoprotein(a) 
and carotid intima media thickness. Disease duration is the best predictor of 
atherosclerosis development in rheumatoid arthritis patients. There were no 
prior studies that linked Serum Lipoprotein (a) levels and Carotid Intima Media 
Thickness in Rheumatoid Arthritis patients to evaluate the cardiovascular risk.  
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CONCLUSION
Inflammatory process of RA simultaneously initiates cardiovascular damage 
and hence early diagnosis of RA is important along with the recognition of 
increased risk of CVD. We have shown an elevated level of Lp(a) in RA 
patients. As the duration of disease increased, Lp(a) levels also increased. Lp(a) 
should be integrated and monitored as independent CV risk factor in existing 
screening tests and treatment algorithms of RA patients.
      Carotid intima media thickness yields a high predictive power for the
development of CV events in RA patients. Carotid ultrasonography could be 
simple non-invasive method of identifying preclinical atherosclerosis.
       In our study no statistically, significant difference in fasting lipid profile in 
RA patients but serum Lp(a) levels are increased. Hence absence of abnormal 
lipid profile does not rule out the possibility of coronary vascular disease in 
these patients.
        The results from the present study support, the use of Carotid 
ultrasonography as a predictor of CV events in RA patients. Subclinical 
atherosclerosis [increase CIMT, Lipoprotein(a)] is common in RA and 
correlated well with disease duration. So, every patient of RA should be 
evaluated for atherosclerosis.
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SUMMARY
          The study of association between Serum Lp(a) and Carotid intima Media 
Thickness and Fasting lipid profile among RA subjects who attended the 
regular OPD was conducted in our institution.
          Adhering strictly to the inclusion and exclusion criteria, 50 cases were 
selected for study. Among them, 47 were females and 3 were males. RA more 
common in females. 50 healthy control subjects were selected for study with 
equivalent age distribution for comparison of study parameters.
              No interference was done in their routine treatment during the study.
              Serum Fasting lipid profile were estimated after standardization using 
IDMS reference calibrator and internal quality control was done. Serum 
Lipoprotein (a) levels were estimated by Immunoturbidimetry method. 
Measuring Carotid Intima Media Thickness on both side of common carotid 
artery – average was taken. Presence of Carotid plaque was also measured.The 
Correlation between Fasting Serum Lp(a), lipid profile and IMT was studied. 
             To conclude, fasting serum Lipoprotein(a) is positively correlated with 
Carotid Intima media thickness in Rheumatoid Arthritis patients. Hence Serum 
Lipoprotein (a) and Carotid Intima Media Thickness can be used for the early 
detection of atherosclerosis and Cardiovascular risk in RA patients.
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LIMITATIONS OF THE STUDY
Further study should be taken to overcome the following limitations.
1.Inclusion of the samples from various geographical distribution.
2.Large sample size will give more information on lipid profile.
3. A long term follow up study can provide much more information about the 
complications of atherosclerosis. 
SCOPE OF THE STUDY.
The findings of this study are only suggestive. A longitudinal study with large 
sample size may be helpful to arrive the spectrum of atherosclerosis changes 
and to evaluate the mortality and morbidity in RA patients.
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PROFORMA
NAME:                                                      AGE/SEX:
OPNO:
PROVISIONAL DIAGNOSIS:
OCCUPATION:
RESIDENCE:
HISTORY of Present illness
H/O Early morning joint stiffness                                                 (YES/NO)
Duration
Involvement of joints                                                          
      Monoarticular < 4joint 
Name 1.                      2.                      3.   4.
Polyarticular   >5joints
H/O fever                                                                                     (YES/NO)
H/O fatigue                                                                                   (YES/NO)
H/O Malaise                                                                                 (YES/NO)
111
H/ODepression (YES/NO)
H/O Cachexia                                                                            (YES/NO)           
Initial  :                        Present weight:                    Muscle fasiculations:                                   
H/O Subcutaneous nodules (YES/NO)           
site:                       size:                   tenderness:
H/O Dry eye/dry mouth  (YES/NO)
H/O Dry Cough/Dyspnea (YES/NO)
H/O Chest pain                                                      (YES/ NO)    
Remission within 6 months                                  (YES/NO) 
PAST HISTORY:
DM                                     HT                                        IHD           
Lung disease  :
h/o cough, fever, pulmonary tuberculosis and treatment:  
Liver disease: H/O jaundice, right hypochondrial pain, abdominal distension:       
Thyroid disorder:H/O hoarseness of voice, constipation, intolerance to cold, 
menstrual irregularities.
Any other illness                                                                                         
112
DRUG HISTROY:  
NSAIDS :
T. Diclofenac, T .Paracetamol,
DMARDS:T.Methotrexate, T.Hydroxy chloroquine, T. Glucocorticoids,
T .Prednisolone
Others 
PERSONAL HISTORY 
Diet
Smoking
Alcohol
Family History
DM                                     HT                                        IHD           
Lung disease                       liver disease                         Thyroid disease       
Any other illness                                                                                         
GENERAL EXAMINATION:
Anaemia    : (YES/NO)
Conjunctiva/nails/tongue- papillae
Jaundice   : (YES/NO)
conjunctiva
Generalised lymphadenopathy     : (YES/NO)
Number/site/size
Pedal Edema  : (YES/NO)
Unilateral /bilateral ;Pitting/non pitting
Nutritional status :
113
Height: Weight:
VITALS:
PULSE RATE : 
Rate:
Rhythm:
Volume:
Site:
BLOOD PRESSURE :              mm/Hg
TEMPERATURE:
LOCALEXAMINATION:                                                                                                                 
Number of the joints involved:  name    1.                     2.                       3.              
            Joint tenderness                                                                                                                
Deformity                                                                                                                                          
Subcutaneous Nodules
SYSTEMIC EXAMINATION:
CARDIOVASCULAR                   : S1:                       S2:
                                                                      MURMUR:
RESPIRATORY                            : NVBS / Any added sounds
ABDOMEN                                     : Hepatomegaly /Splenomegaly 
CENTRAL NERVOUS SYSTEM :
CRANIAL NERVE EXAMINATION:
MOTOR SYSTEM:
SENSORY SYSTEM:
REFLEXS:
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PATIENT CONSENT FORM
Name:     Age / sex:      OP No :
               I herewith declare that I have been understood the study (title-
“Association of Lipoprotein (a) and Carotid intima media thickness  in 
Rheumatoid Arthritis patients in prediction of Cardiovascular risk”) in a 
local language and have fully understood the purpose of this study; 
methodology, proposed intervention, plausible side effects if any and sequelae.
I have been given the opportunity to discuss my doubts and I have received the 
appropriate explanation.I understand that my participation in this study is 
completely voluntary and that they are free to be withdrawn from this study at 
any point of time without prior notice or without having their medical or legal 
rights affected.
I permit the author and the research team full access to all their records at any 
point of time even if I have withdrawn from the study. However their identity 
will not be revealed to any third party or publication.
I herewith permit the author and the research team to use the results and 
conclusions arising from this study for any academic purpose, including but not 
limited to dissertation/thesis or publication or presentation in any 
level.Therefore in my full conscience give consent to include me in the study 
and undergo any investigation or any intervention therein.
Patient’s sign /Date                                                                  Investigator’s sign
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117
MASTER CHART FOR CONTROLS
S.No Age Sex T.Chol TGL VLDL LDL HDL NonHDL Lp(a) 
CAROTID 
ARTERY 
DOPPLER                     
IMT-R     IMT-L PLAQUES
1 53 F 140 42 8 86 46 94 8 0.4 0.4 -
2 35 F 197 128 26 135 36 161 25 0.4 0.5 -
3 41 F 221 138 28 149 44 177 11 0.5 0.5 -
4 46 F 159 67 13 110 36 123 6 0.4 0.5 -
5 55 F 179 131 26 106 47 132 7 0.3 0.4 -
6 65 F 215 108 22 142 51 164 16 0.2 0.3 -
7 46 F 140 71 14 90 36 104 10 0.3 0.3 -
8 50 F 186 72 14 139 33 153 7 0.4 0.4 -
9 45 M 202 183 37 123 42 160 19 0.4 0.4 -
10 27 F 184 154 31 119 34 150 23 0.3 0.4 -
11 47 F 217 125 25 137 55 162 26 0.4 0.4 -
12 30 F 120 98 20 84 16 104 9 0.6 0.6 -
13 40 F 198 211 42 108 48 150 17 0.4 0.3 -
14 55 F 175 110 22 115 38 137 4.7 0.5 0.4 -
15 52 F 185 92 18 137 30 155 18 0.4 0.5 -
16 49 F 184 115 23 117 44 140 9 0.3 0.3 -
17 39 F 159 102 20 80 59 100 10 0.6 0.4 -
18 52 M 178 91 18 116 44 134 25 0.3 0.5 -
19 38 F 143 69 14 83 46 97 14 0.3 0.3 -
20 29 F 197 129 26 114 57 140 28 0.2 0.3 -
21 32 F 203 178 36 125 42 161 17 0.3 0.4 -
22 49 F 170 179 36 86 48 122 20 0.4 0.3 -
23 47 F 183 114 23 109 51 132 11 0.3 0.4 -
24 57 F 159 94 19 100 40 119 15 0.3 0.4 -
25 46 F 172 152 30 106 36 136 13 0.4 0.5 -
26 33 F 170 115 23 112 35 135 12 0.3 0.3 -
27 40 F 272 168 33 171 65 207 29 0.4 0.6 -
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28 37 F 172 154 31 86 55 117 72 0.3 0.5 -
29 42 F 186 136 27 114 45 141 11 0.3 0.3 -
30 56 F 162 125 25 90 47 115 21 0.2 0.3 -
31 44 F 150 141 28 90 32 118 14 0.4 0.5 -
32 37 F 195 70 14 125 56 139 16 0.5 0.4 -
33 41 M 188 68 14 110 64 101 9 0.3 0.3 -
34 51 F 158 109 22 101 35 123 13 0.3 0.4 -
35 39 F 176 97 19 88 69 107 13.6 0.3 0.3 -
36 32 F 196 76 15 137 44 152 14 0.3 0.3 -
37 58 F 214 166 33 119 62 152 23 0.4 0.3 -
38 48 F 110 127 25 48 37 73 8 0.5 0.4 -
39 34 F 208 146 29 111 68 140 21 0.3 0.4 -
40 28 F 179 97 20 103 56 123 19 0.4 0.3 -
41 43 F 182 114 23 120 41 141 33 0.3 0.5 -
42 53 F 138 141 28 71 39 99 5.5 0.2 0.3 -
43 59 F 156 145 29 57 70 86 13 0.4 0.5 -
44 51 F 158 135 27 91 40 118 14 0.3 0.3 -
45 49 F 132 126 26 69 37 95 30 0.6 0.5 +
46 36 F 172 128 26 105 41 131 24 0.5 0.3 -
47 47 M 173 128 24 85 64 109 36 0.3 0.3 -
48 41 F 168 120 25 88 55 113 16 0.4 0.3 -
49 53 F 204 125 25 133 46 158 5.5 0.3 0.4 -
50 58 F 172 132 27 91 54 118 11 0.4 0.3 -
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MASTER CHART FOR CASES
S.N
o
Ag
e  
(Yr
s)
Se
x
Dur
atio
n of 
RA  
(Yrs
)
T.Ch
ol
TG
L 
VLD
L LDL 
HD
L 
Non
HDL
Lp(a
)
CAROTID 
ARTERY 
DOPPLER                     
IMT-R     
IMT-L
PLA
QUE
S
RA                  
fact
or
1 52 F 9 196 110 23 130 43 153 59 0.7 0.6 + +
2 44 F 5 142 80 17 83 42 100 15 0.5 0.5 - +
3 53 F 4 159 144 33 75 51 108 22 0.4 0.5 - +
4 50 F 6 157 149 44 66 47 110 14 0.3 0.4 - +
5 50 F 4 175 77 15 124 36 139 21 0.5 0.5 - +
6 53 F 15 237 146 29 159 49 188 72 0.8 0.7 - +
7 53 F 5 220 101 20 143 57 163 23 0.5 0.4 - +
8 46 F 6 253 85 17 184 52 201 29 0.5 0.5 - +
9 53 F 4 183 143 35 100 48 135 41 0.7 0.7 + +
10 29 F 7 181 114 23 120 38 143 36 0.6 0.7 - +
11 60 F 15 150 87 17 79 54 96 23 0.5 0.5 - +
12 30 F 11 150 95 19 95 36 114 42 0.5 0.5 - +
13 46 F 4 175 85 17 111 47 128 18 0.5 0.4 - +
14 38 F 3 220 180 36 131 53 167 21 0.5 0.5 - +
15 60 F 3.5 119 82 16 60 40 79 18 0.4 0.3 - +
16 53 F 15 201 95 19 129 63 138 54 0.8 0.7 + +
17 30 F 3 213 143 29 139 52 161 16 0.3 0.3 -
18 40 F 4.7 204 84 17 143 44 160 26 0.5 0.5 - +
19 34 F 6 157 112 22 117 18 139 27 0.4 0.4 - +
20 46 F 14 180 67 13 131 36 144 89 0.9 0.8 - +
21 50 F 15 160 96 10 74 47 113 29 0.5 0.5 + +
22 53 F 3 193 81 16 132 45 148 41 0.7 0.6 - +
23 43 F 5 159 75 15 89 55 104 22 0.5 0.5 - +
24 50 F 2 195 136 27 134 37 158 18 0.5 0.6 - +
25 33 M 8 139 97 19 93 27 112 17 0.4 0.4 - +
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26 29 F 4 163 69 14 102 47 116 22 0.4 0.5 - +
27 43 F 3 180 122 24 126 30 150 18 0.5 0.5 - +
28 53 F 10 201 128 54 154 45 156 44 0.6 0.6 - +
29 48 F 3 227 118 24 141 62 165 46 0.7 0.6 + +
30 45 F 3.5 230 111 22 160 48 182 29 0.5 0.5 - +
31 60 F 10 196 117 19 123 50 146 36 0.6 0.5 + +
32 44 F 3.6 140 109 22 81 37 103 10 0.3 0.3 - +
33 44 M 2 165 130 26 87 52 113 44 0.7 0.6 - +
34 60 F 12 138 52 10 75 52 86 26 0.4 0.4 - +
35 59 F 15 154 54 11 87 56 98 57 0.6 0.8 - +
36 49 F 6 169 156 31 87 51 118 20 0.4 0.5 - +
37 52 F 7 153 85 17 80 56 97 33 0.5 0.5 - +
38 42 F 5 171 98 20 102 49 122 20 0.3 0.3 - +
39 38 F 7 144 116 23 80 41 103 34 0.6 0.7 - +
40 46 F 4 186 126 25 105 56 130 22 0.4 0.4 + +
41 55 F 10 194 172 34 123 37 157 45 0.7 0.6 - +
42 38 F 5.7 230 138 28 168 34 191 29 0.5 0.4 - +
43 49 F 5 164 141 29 87 48 116 22 0.4 0.4 - +
44 52 F 4 110 91 18 43 49 61 23 0.5 0.5 - +
45 46 F 3.5 138 94 19 72 47 91 20 0.4 0.3 - +
46 49 F 11 197 141 28 139 30 167 63 0.8 0.7 + +
47 49 F 8 210 138 28 141 41 169 55 0.7 0.6 + +
48 55 M 7 118 168 34 90 64 54 59 0.7 0.7 - +
49 38 F 3 135 189 38 64 33 102 13 0.3 0.3 - +
50 59 F 8 196 110 22 135 39 157 41 0.6 0.5 - +
